OSI Pharmaceuticals Announces That “RADIANT”, an International Phase III Tarceva Adjuvant Trial in Non-Small Cell Lung …
MELVILLE, N.Y.—-OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva® as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

Read more on Business Wire via Yahoo! Finance